Please provide your email address to receive an email when new articles are posted on . For the open-label COVID-19 Cardiolink-9 study, the researchers randomly assigned 100 symptomatic patients with ...
Patients in the placebo arm of REDUCE-IT, who received mineral oil, saw worsening levels of numerous biomarkers linked to atherosclerotic disease during the trial, while those in the icosapent ethyl ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Icosapent ethyl as an adjunct to statin therapy ...
Much like in the overall REDUCE-IT trial, icosapent ethyl (Vascepa; Amarin) reduced a broad range of adverse clinical outcomes in the large subgroup of patients who had undergone a prior PCI, a ...
The mechanism behind the cardiovascular benefits of icosapent ethyl (Vascepa) was related to plaque regression and stabilization in people with atherosclerotic cardiovascular disease (ASCVD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results